Skip to main content
. 2018 Jul 13;8:60. doi: 10.1186/s13550-018-0419-z

Table 1.

Baseline characteristics of patients

Characteristic N or mean ± SD
Sex
 Male 8 (33%)
 Female 16 (67%)
Age (year) 66 ± 11
Previous systemic therapy
 Bevacizumab 14 (58%)
 Cetuximab 3 (12%)
 Irinotecan 5 (21%)
 Panitunumab 1 (4%)
Tumour burden (% of whole liver)
 < 10% 16 (66%)
 > 10% 8 (34%)
Metabolic tumour volume (ml) 99 ± 98
90Y-microsphere prescribed activity (MBq) 1120 ± 503
Treatment
 Whole liver 6 (25%)
 Lobar 15 (63%)
 Supra-selective 3 (12%)